Daniel J Hicklin

Summary

Affiliation: ImClone Systems
Country: USA

Publications

  1. ncbi Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    Daniel J Hicklin
    Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY 10014, USA
    J Clin Oncol 23:1011-27. 2005
  2. ncbi Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member
    Jennifer M O'Toole
    Department of Tumor Biology, ImClone Systems, Inc, New York, NY 10014, USA
    Cancer Res 66:9162-70. 2006
  3. ncbi Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab
    Marie Prewett
    Department of Preclinical Pharmacology, ImClone Systems Incorporated, New York, NY 10014, USA
    Clin Cancer Res 13:7432-40. 2007
  4. ncbi Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer
    Yan Wu
    Department of Experimental Therapeutics, ImClone Systems, Inc, New York, New York 10014, USA
    Clin Cancer Res 12:6573-84. 2006
  5. ncbi The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma
    Yan Wu
    Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, New York 10014, USA
    Int J Cancer 119:1519-29. 2006
  6. ncbi Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature
    Chad May
    ImClone Systems Incorporated, 180 Varick St, New York, NY 10014, USA
    Blood 105:4337-44. 2005
  7. ncbi Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies
    Dipa Patel
    Department of Experimental Therapeutics and Protein Science, ImClone Systems Incorporated, New York, NY 10014, USA
    Anticancer Res 28:2679-86. 2008
  8. ncbi A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity
    Dan Lu
    Department of Antibody Technology, New York, New York 10014, USA
    J Biol Chem 280:19665-72. 2005
  9. ncbi Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation
    Dipa Patel
    ImClone Systems Incorporated, New York, NY, USA
    Int J Oncol 34:25-32. 2009
  10. ncbi Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy
    James R Tonra
    ImClone Systems Inc, New York, New York, USA
    Clin Cancer Res 12:2197-207. 2006

Collaborators

Detail Information

Publications73

  1. ncbi Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    Daniel J Hicklin
    Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY 10014, USA
    J Clin Oncol 23:1011-27. 2005
    ....
  2. ncbi Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member
    Jennifer M O'Toole
    Department of Tumor Biology, ImClone Systems, Inc, New York, NY 10014, USA
    Cancer Res 66:9162-70. 2006
    ..Taken together, our results highlight the potential therapeutic usefulness of RON activity inhibition in human cancers...
  3. ncbi Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab
    Marie Prewett
    Department of Preclinical Pharmacology, ImClone Systems Incorporated, New York, NY 10014, USA
    Clin Cancer Res 13:7432-40. 2007
    ....
  4. ncbi Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer
    Yan Wu
    Department of Experimental Therapeutics, ImClone Systems, Inc, New York, New York 10014, USA
    Clin Cancer Res 12:6573-84. 2006
    ....
  5. ncbi The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma
    Yan Wu
    Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, New York 10014, USA
    Int J Cancer 119:1519-29. 2006
    ..The results suggest that VEGF receptors may not only modulate angiogenesis, but also directly influence the growth of VEGF receptor expressing tumors...
  6. ncbi Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature
    Chad May
    ImClone Systems Incorporated, 180 Varick St, New York, NY 10014, USA
    Blood 105:4337-44. 2005
    ..Our findings establish the immediate N-terminal region of VE-cadherin as a novel target for inhibiting angiogenesis...
  7. ncbi Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies
    Dipa Patel
    Department of Experimental Therapeutics and Protein Science, ImClone Systems Incorporated, New York, NY 10014, USA
    Anticancer Res 28:2679-86. 2008
    ..05). A combined modality approach that provides passive immunity to melanoma differentiation antigens as well as inhibiting tumor neovascularization may be valuable for the treatment of malignant melanoma...
  8. ncbi A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity
    Dan Lu
    Department of Antibody Technology, New York, New York 10014, USA
    J Biol Chem 280:19665-72. 2005
    ..Finally, the Di-diabody strongly inhibited the growth of two different human tumor xenografts in vivo. Our results underscore the benefits of simultaneous targeting of two tumor targets with bispecific antibodies...
  9. ncbi Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation
    Dipa Patel
    ImClone Systems Incorporated, New York, NY, USA
    Int J Oncol 34:25-32. 2009
    ..These results suggest that cetuximab may be useful in the treatment of carcinomas co-expressing EGFR and HER2...
  10. ncbi Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy
    James R Tonra
    ImClone Systems Inc, New York, New York, USA
    Clin Cancer Res 12:2197-207. 2006
    ..Here, we have evaluated the interaction between anti-EGFR antibody Erbitux (cetuximab) and anti-VEGFR2 antibody, DC101, in preclinical models of pancreatic (BxPC-3) and colon (GEO) cancer...
  11. pmc Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling
    Loic Vincent
    Department of Genetic Medicine and Division of Hematology and Oncology, Howard Hughes Medical Institute, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Clin Invest 115:2992-3006. 2005
    ....
  12. doi In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2
    James R Tonra
    ImClone Systems Inc, New York, NY, USA
    Methods Mol Biol 525:545-57, xv. 2009
    ....
  13. ncbi Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor
    Philipp Steiner
    ImClone Systems Incorporated, New York, New York 10014, USA
    Clin Cancer Res 13:1540-51. 2007
    ..We analyzed the effects of the monoclonal IgG1 antibody Erbitux (cetuximab) in NSCLC xenografts with wild-type (wt) or mutated EGFR...
  14. ncbi Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1
    Dipa Patel
    ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, USA
    Hum Antibodies 16:127-36. 2007
    ..These results suggest that human anti-TYRP1 MAb may be a potent therapeutic for the treatment of malignant melanoma...
  15. ncbi Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody
    Yiwen Li
    Department of Immunology, ImClone Systems, 180 Varick St, New York, NY 10014, USA
    Blood 104:1137-44. 2004
    ..Taken together, these data demonstrate that IMC-EB10 is a specific and potent inhibitor of wild-type and ITD-mutant FLT3 and that it deserves further study for targeted therapy of human AML...
  16. ncbi Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target
    Nick Loizos
    Department of Protein Chemistry, ImClone Systems, Inc, 180 Varick Street, New York, NY 10014, USA
    Mol Cancer Ther 4:369-79. 2005
    ..Antibody 3G3 significantly inhibited the growth of U118 (P=0.0004) and SKLMS-1 (P <0.0001) tumors relative to control. These data suggest that 3G3 may be useful for the treatment of tumors that express PDGFRalpha...
  17. ncbi Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells
    Loic Vincent
    Department of Genetic Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Res 65:3185-92. 2005
    ....
  18. ncbi Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed
    Dale L Ludwig
    ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, USA
    Hum Antibodies 13:81-90. 2004
    ....
  19. pmc Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes
    David K Jin
    Department of Genetic Medicine, Division of Hematology Medical Oncology, Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA
    Nat Med 12:557-67. 2006
    ..Delivery of SDF-1 may be effective in restoring angiogenesis in individuals with vasculopathies...
  20. ncbi Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo
    Eunice S Wang
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 104:2893-902. 2004
    ..12, methotrexate) consistently improved tumor responses over those of single-agent therapy. These data support the further clinical development of VEGFR-targeted approaches for the therapy of aggressive DLBCL...
  21. ncbi A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo
    Douglas Burtrum
    ImClone Systems Incorporated, New York, New York 10014, USA
    Cancer Res 63:8912-21. 2003
    ....
  22. pmc Vascular endothelial growth factor receptor 2 (VEGFR-2) functions to promote uterine decidual angiogenesis during early pregnancy in the mouse
    Nataki C Douglas
    Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Columbia University, New York, New York 10032, USA
    Endocrinology 150:3845-54. 2009
    ..This newly formed decidual vasculature serves as the first exchange apparatus for the developing embryo until the placenta becomes functionally active...
  23. ncbi Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface
    Dipa Patel
    Departments of Experimental Therapeutics, ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, USA
    Anticancer Res 27:3355-66. 2007
    ..EGFR variant III (EGFRvIII) is a truncated form of EGFR that does not bind ligand, is constitutively active, and is reported to be coexpressed with EGFR in some human tumors including breast, glioblastoma, lung, and prostate...
  24. ncbi Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody
    Bronislaw Pytowski
    Molecular and Cellular Biology, ImClone Systems, New York, NY, USA
    J Natl Cancer Inst 97:14-21. 2005
    ..However, the exact role of VEGFR-3 signaling in adult lymphangiogenesis and in lymphatic vessel survival and regeneration is unclear...
  25. ncbi Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis
    Scott T Avecilla
    Department of Medicine, Division of Hematology Oncology, Cornell University Medical College, 1300 York Avenue, New York, New York 10021, USA
    Nat Med 10:64-71. 2004
    ..Progenitor-active chemokines offer a new strategy to restore hematopoiesis in a clinical setting...
  26. ncbi Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts
    Marie C Prewett
    Department of Immunology, ImClone Systems, Inc, New York, New York 10014, USA
    Clin Cancer Res 8:994-1003. 2002
    ..These results suggest that EGFR blockade by IMC-C225 combined with topoisomerase I inhibitors may be an effective therapy against chemorefractory colorectal carcinoma tumors...
  27. pmc mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    Kathryn E O'Reilly
    Program in Molecular Pharmacy and Chemistry, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Res 66:1500-8. 2006
    ..Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity...
  28. ncbi Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy
    James R Tonra
    ImClone Systems Incorporated, New York, New York, USA
    Immunol Invest 36:3-23. 2007
    ....
  29. ncbi Monoclonal antibody therapeutics and apoptosis
    Dale L Ludwig
    ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, USA
    Oncogene 22:9097-106. 2003
    ..This review will focus on the mechanisms by which antibodies are capable of eliciting programmed cell death either directly or indirectly within tumor cells...
  30. pmc Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment
    Koichi Hattori
    Department of Medicine, Cornell University Medical College, New York, New York, USA
    Nat Med 8:841-9. 2002
    ..Thus, PlGF promotes recruitment of VEGFR1(+) HSCs from a quiescent to a proliferative BM microenvironment, favoring differentiation, mobilization and reconstitution of hematopoiesis...
  31. ncbi Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy
    Yiwen Li
    ImClone Systems, Incorporated Department of Immunology, New York, NY 10014, USA
    Curr Mol Med 3:773-9. 2003
    ..This review provides an outline of this emerging field and discusses the advantages and potential pitfalls of such a vaccine strategy...
  32. pmc Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis
    Yiwen Li
    ImClone Systems Incorporated, New York, NY 10014, USA
    J Exp Med 195:1575-84. 2002
    ..Thus, an active immunization strategy that targets an angiogenesis-related antigen on endothelium can inhibit angiogenesis and may be a useful approach for treating angiogenesis-related diseases...
  33. ncbi Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models
    James R Tonra
    ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, New York, NY10014, U S A
    Anticancer Res 29:1999-2007. 2009
    ..Rational strategies utilizing anticancer efficacy and biological principles are needed for the prioritization of specific combination targeted therapy approaches for clinical development, from among the many with experimental support...
  34. ncbi Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy
    Hagop Youssoufian
    Clinical Affairs Department, ImClone Systems, Inc, Branchburg, New Jersey 08876, USA
    Clin Cancer Res 13:5544s-5548s. 2007
    ..Here, we discuss the role of VEGFR-2 in cancer and ongoing efforts to develop highly specific monoclonal antibodies for cancer therapy...
  35. ncbi Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability
    Fang Liao
    ImClone Systems Incorporated, New York, NY 10014, USA
    Cancer Res 62:2567-75. 2002
    ..Our data also suggest that antibody E4G10 recognizes VE-cadherin epitopes that are only accessible on endothelial cells forming new adherens junctions, such as in angiogenic tumor vasculature...
  36. ncbi Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Nat Med 8:831-40. 2002
    ..Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation...
  37. ncbi Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target
    E Ramsay Camp
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:1030-9. 2007
    ..It was hypothesized that RON, a tyrosine kinase receptor related to c-MET, would be expressed in human pancreatic cancer cells, induce EMT, and would thus serve as a target for therapy in a preclinical model...
  38. ncbi Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
    Yuval Shaked
    Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    Science 313:1785-7. 2006
    ..These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs...
  39. ncbi A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability
    Monica Corada
    FIRC Institute of Molecular Oncology, Milan, Italy
    Blood 100:905-11. 2002
    ..In contrast, in growing vessels, where endothelial cells are migrating and junctions are weaker, antibody binding to EC4 may be sufficient to disrupt cell-to-cell adhesion and inhibit assembly of new vascular structures...
  40. ncbi Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 produc
    Paul Sweeney
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2714-24. 2002
    ..The aim of the present study was to evaluate the response of orthotopic prostate cancer xenografts and prostate cancer bone metastasis to anti-VEGF receptor (flk-1) antibody (DC101) treatment...
  41. ncbi Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance
    Lianglin Zhang
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 66:8770-8. 2006
    ..In the future, such therapeutic approaches may be useful in treating STS before the development of clinically apparent metastases...
  42. ncbi Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
    Chris Folkins
    Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Cancer Res 67:3560-4. 2007
    ....
  43. ncbi Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies
    Alison M Y Cheung
    Imaging Research, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON, Canada
    Ultrasound Med Biol 33:1259-68. 2007
    ..Our study investigates tumour response to DC101 using complementing micro-ultrasound and micro-CT imaging tools...
  44. ncbi Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors
    Sergey V Kozin
    Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 67:5076-82. 2007
    ..Our findings suggest that antiangiogenic agents could be effective in the treatment of patients with relapses after radiotherapy...
  45. ncbi A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
    Elizabeth A Manning
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 13:3951-9. 2007
    ....
  46. pmc Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system
    Oliver Stoeltzing
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Cancer Lett 258:291-300. 2007
    ..Similarly, treatment with an anti-IGF-IR antibody effectively inhibited IGF-IR and MAPK/Erk activation and decreased COX-2 in parental cells. In conclusion, activation of IGF-IR mediates COX-2 expression in human pancreatic cancer cells...
  47. ncbi Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
    Shan Man
    Departments of Medical Biophysics, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5 Canada
    Cancer Res 62:2731-5. 2002
    ..o. metronomic chemotherapy regimen, which proved safe, reasonably efficacious, and potentially applicable to chronic treatment. Such a regimen may be particularly well suited for integration with antiangiogenic drugs...
  48. ncbi Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice
    Takashi Karashima
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 8:1253-64. 2002
    ..The simultaneous administration of paclitaxel enhanced this effect...
  49. ncbi Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis
    Lianglin Zhang
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:2034-42. 2002
    ..Collectively, our data suggested that anti-VEGF receptor 2 in combination with continuous low-dose doxorubicin may provide a new therapeutic approach for human soft tissue sarcoma in the clinic...
  50. ncbi Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara Nara, Japan
    Hepatology 35:834-42. 2002
    ..In conclusion, these results suggest that bFGF synergistically augments VEGF-mediated HCC development and angiogenesis at least partly by induction of VEGF through KDR/Flk-1...
  51. ncbi Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme
    Jorge L Eller
    Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse 13210, USA
    Neurosurgery 51:1005-13; discussion 1013-4. 2002
    ..The purpose of this study was to analyze whether blocking this receptor with the anti-EGFR chimeric monoclonal antibody C225 would decrease proliferation and increase apoptosis in GBM cells...
  52. ncbi Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice
    Christiane J Bruns
    Departments of Cancer Biology and Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Cancer 102:101-8. 2002
    ..Anti-VEGF receptor-2 therapy in combination with gemcitabine may be a novel therapeutic approach for advanced pancreatic cancer...
  53. ncbi Effect of p53 status on tumor response to antiangiogenic therapy
    Joanne L Yu
    Sunnybrook and Women s College Health Sciences Centre, Molecular and Cellular Biology Research, Room S 218, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Science 295:1526-8. 2002
    ....
  54. ncbi Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice
    Obdulio Piloto
    Department of Oncology and Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 65:1514-22. 2005
    ..Thus, these types of antibodies have the potential to be safe and effective new therapeutic agents for acute myelogenous leukemia and possibly other FLT3-expressing malignancies...
  55. ncbi Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
    Yuval Shaked
    Department of Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario M3N 4M5, Canada
    Cancer Cell 7:101-11. 2005
    ..Finally, treatment with a targeted VEGFR-2 antibody caused a dose-dependent reduction in viable CEPs that precisely paralleled its previously and empirically determined antitumor activity...
  56. ncbi Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development
    Peetra Magnusson
    Department of Genetics and Pathology, Uppsala University, Rudbeck Laboratory, Dag Hammarskjoldsv 20, 751 85 Uppsala, Sweden
    J Cell Sci 117:1513-23. 2004
    ..We conclude that VEGF-A/VEGFR-2-dependent vessel formation occurs in the absence of FGF-2/FGFR-1, which, however, serve to modulate vascular development...
  57. ncbi Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo
    Jorge L Eller
    Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse, New York 13210, USA
    Neurosurgery 56:155-62; discussion 162. 2005
    ..The purpose of the present work was to study further the effectiveness of cetuximab as a monotherapy as well as combining it with radiation therapy or chemotherapy...
  58. ncbi Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
    ..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation...
  59. ncbi Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
    Ricky T Tong
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 64:3731-6. 2004
    ..Thus, vascular normalization may contribute to the improved survival rates in tumor-bearing animals and in colorectal carcinoma patients treated with an anti-VEGF antibody in combination with cytotoxic therapies...
  60. ncbi Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts
    Darren W Davis
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 64:4601-10. 2004
    ..Thus, agents that target a single receptor (e.g., VEGFR-2) may not be sufficient to completely inhibit tumor angiogenesis...
  61. ncbi Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice
    Andrew R Reynolds
    Tumour Biology Laboratory, Cancer Research UK Clinical Centre, Barts and The London, Queen Mary s School of Medicine and Dentistry, John Vane Science Centre, London, United Kingdom
    Cancer Res 64:8643-50. 2004
    ..These data confirm that VEGF signaling via Flk1 is enhanced in beta(3)-integrin-deficient mice and suggests that this increase may mediate the enhanced angiogenesis and tumor growth observed in these mice in vivo...
  62. ncbi Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
    Monica Autiero
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KULeuven, Leuven, B 3000, Belgium
    Nat Med 9:936-43. 2003
    ....
  63. ncbi Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro
    Jean Christophe Tille
    Department of Cell Biology and Morphology, University Medical Center, Geneva, Switzerland
    Exp Cell Res 285:286-98. 2003
    ..Taken together, these findings point to the central role of VEGFR-2 in the angiogenic signaling pathways induced by VEGF-C(deltaNdeltaC) and VEGF-A...
  64. ncbi Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer
    E Ramsay Camp
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 12:2628-33. 2006
    ..Because these molecules regulate one another's expression, we hypothesized that NO synthase (NOS) inhibition produces effects comparable to those of anti-VEGF therapy on human pancreatic cancer xenografts...
  65. ncbi Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
    Donald J Buchsbaum
    Department of Radiation Oncology, University of Alabama at Birmingham, Wallace Tumor Institute, Room 674, 1824 6th Avenue South, Birmingham, AL 35294, USA
    Int J Radiat Oncol Biol Phys 54:1180-93. 2002
    ..To investigate treatment of human pancreatic cancer cell lines and xenografts with combinations of Erbitux (IMC-C225) anti-epidermal growth factor receptor (EGFR) antibody, gemcitabine, and radiation...
  66. ncbi Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
    Marcela Franco
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Cancer Res 66:3639-48. 2006
    ..The implications of the results are discussed, particularly with respect to how they relate to different theories for the counterintuitive chemosensitizing effects of antiangiogenic drugs, even when hypoxia is increased...
  67. ncbi Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts
    Jeanne M du Manoir
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Clin Cancer Res 12:904-16. 2006
    ..The basis of this acquired resistance is unknown, hampering strategies to delay or treat such acquired resistance, due in part to the relative lack of appropriate in vivo tumorigenic models...
  68. ncbi Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
    Guido Bocci
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Cancer Res 64:6616-25. 2004
    ..Plasma VEGF should be considered as a possible surrogate pharmacodynamic marker for determining the optimal biological dose of antibody drugs that block VEGFR-2 (KDR) activity in a clinical setting...
  69. ncbi Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose
    Yuval Shaked
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Curr Cancer Drug Targets 5:551-9. 2005
    ..Finally, another promising marker we discuss is soluble VEGFR-2...
  70. pmc Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants
    Daniel W Miller
    Division of Differentiation and Carcinogenesis A080, German Cancer Research Center, and the Department of Ophthalmology, University of Heidelberg Hospitals and Clinics, Germany
    Am J Pathol 167:1389-403. 2005
    ..Thus, short-term inhibition of VEGF signaling results in complex stromal alterations with crucial consequences for the tumor phenotype...
  71. ncbi Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    Oriol Casanovas
    Department of Biochemistry and Biophysics, Comprehensive Cancer Center, and Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
    Cancer Cell 8:299-309. 2005
    ..These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition...
  72. ncbi Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts
    Yotaro Izumi
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 63:747-51. 2003
    ..Although passaged tumors behave differently, it is encouraging that the tumor growth rates under DC101 treatment are comparable among different passage generations...
  73. ncbi Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity
    Hideaki Watanabe
    Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287 0900, USA
    Exp Dermatol 13:671-81. 2004
    ..Our findings suggest that DC101 could function by reducing inflammatory cell migration and hence IFN-gamma expression during the CHS response...